Proteasome inhibitors in multiple myeloma: 10 years later

Proteasome inhibition has emerged as an important therapeutic strategy in multiple myeloma (MM). Since the publication of the first phase 1 trials of bortezomib 10 years ago, this first-in-class proteasome inhibitor (PI) has contributed substantially to the observed improvement in survival in MM pat...

Full description

Saved in:
Bibliographic Details
Main Authors: Moreau, Philippe, Richardson, Paul G., Cavo, Michele, Orlowski, Robert Z., San Miguel, Jesús F., Palumbo, Antonio, Harousseau, Jean-Luc
Format: Artigo
Language:Inglês
Published: American Society of Hematology 2012
Subjects:
Review Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4123429/
https://ncbi.nlm.nih.gov/pubmed/22645181
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-04-403733
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items